The CLARICOR Trial: Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease
Status:
Completed
Trial end date:
2002-09-01
Target enrollment:
Participant gender:
Summary
A growing body of evidence links Chlamydia pneumoniae to the progression of coronary heart
disease. The purpose of this study is to determine the positive and negative effect of 14
days treatment with clarithromycin 500 mg daily in patients already suffering from stable
coronary heart disease. The participants will be followed for at least two years after the
treatment.
Abbott Laboratories supplied Clarithromycin and placebo tablets.
Phase:
Phase 3
Details
Lead Sponsor:
Copenhagen Trial Unit, Center for Clinical Intervention Research
Collaborators:
Abbott Copenhagen Hospital Corporation Danish Heart Foundation The 1991 Pharmacy Foundation The Danish Medical Research Council